<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128958</url>
  </required_header>
  <id_info>
    <org_study_id>CF102-201HCC</org_study_id>
    <nct_id>NCT02128958</nct_id>
  </id_info>
  <brief_title>Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in
      subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1
      prior systemic drug therapy for HCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will evaluate the efficacy and safety of CF102 as compared to placebo. Subjects
      will be randomly assigned in a 2:1 ratio to treatment with oral doses of either CF102 25 mg
      or matching placebo administered twice daily (BID) for consecutive, 28-day cycles. Subjects
      will be evaluated regularly for safety. Tumor imaging will be performed every 8 weeks.
      Treatment will continue until the subject experiences unacceptable drug-related
      intolerability. Subjects will return for a follow-up visit 28 days after completion of the
      last dose of study drug, and every attempt will be made to obtain survival data on all
      randomized subjects. Subjects who discontinue will be followed indefinitely for survival
      status. The trial will continue until 75 deaths have been recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>28-day cycles</time_frame>
    <description>Evaluate the efficacy of orally administered CF102 25 mg twice daily (BID) as compared to placebo, as determined by Overall Survival (OS), when used as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B (CPB) cirrhosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>28-day cycles</time_frame>
    <description>Evaluate other indicators of efficacy of CF102 as compared to placebo, including time to progression (TTP), progression-free survival (PFS), objective response (OR) rate, and disease control (DC) rate in this population;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>28-day cycles</time_frame>
    <description>Characterize the safety profile of CF102 in subjects with advanced HCC and CPB cirrhosis;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory parameters of hepatic dysfunction and viral hepatitis</measure>
    <time_frame>28-day cycles</time_frame>
    <description>Characterize the effects of CF102 on laboratory parameters associated with viral hepatitis, hepatic dysfunction, and cirrhosis;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adenosine A3 receptor (A3AR) expression</measure>
    <time_frame>28-day cycles</time_frame>
    <description>Explore the relationship between white blood cell (WBC) adenosine A3 receptor (A3AR) expression and clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of CF102 in this population</measure>
    <time_frame>Cycle 1 days 1, 8 and 15. Cycle 2 day 1</time_frame>
    <description>Explore exposure-response relationships using sparse pharmacokinetic (PK) sampling;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CF102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally q12h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets of CF102</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>orally q12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF102</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>CF102</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally q12 hours</description>
    <arm_group_label>Placebo tablets of CF102</arm_group_label>
    <other_name>Inactive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females at least 18 years of age.

          2. Diagnosis of HCC:

               -  For subjects without underlying cirrhosis at the time of diagnosis, diagnosis of
                  HCC documented by cytology and/or histology.

               -  For subjects with underlying cirrhosis at the time of diagnosis, diagnosis of HCC
                  established according to the American Association for the Study of Liver Diseases
                  Practice Guideline algorithm (Appendix E).

          3. HCC is advanced, ie, treatment-refractory or metastatic, and no standard therapies are
             expected to be curative.

          4. Receipt of 1 previous systemic drug therapy for at least 3 weeks and withdrawal from
             treatment due either to intolerability or to radiographic disease progression. If
             treatment was withdrawn due to intolerability manifested as a Grade 3 or 4 event by
             National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE v4.0),
             less than 3 weeks of continuous prior administration prior to withdrawal is acceptable
             (see also Exclusion Criterion #3).

          5. Prior systemic treatment was discontinued for at least 2 weeks prior to the Baseline
             Visit.

          6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2 (Appendix B).

          7. Cirrhosis classified as Child-Pugh Class B (Appendix C).

          8. The following laboratory values must be documented within 3 days prior to the first
             dose of study drug:

               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

               -  Platelet count ≥ 75 × 109/L

               -  Serum creatinine ≤ 2.0 mg/dL

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × the
                  upper limit of normal (ULN)

               -  Total bilirubin ≤ 3.0 mg/dL

               -  Serum albumin ≥ 2.8 g/dL

               -  Prothrombin time (PT) no greater than 6 seconds longer than control.

          9. Life expectancy of ≥ 6 weeks.

        Exclusion Criteria:

          1. Receipt of no, or of &gt;1, prior systemic drug therapies for HCC.

          2. Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive
             therapy, or corticosteroids &gt; 20 mg/day prednisone or equivalent within 14 days prior
             to the Baseline Visit or concurrently during the trial.

          3. Presence of an acute or chronic toxicity of prior chemotherapy that has not resolved
             to ≤ Grade 1, as determined by CTCAE v 4.0.

          4. Locoregional treatment within 4 weeks prior to the Baseline Visit.

          5. Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit.

          6. Use of any investigational agent within 4 weeks prior to the Baseline Visit.

          7. Child-Pugh Class A or C cirrhosis, or hepatic encephalopathy.

          8. Occurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion
             within 4 weeks prior to the Baseline Visit.

          9. Active bacterial, viral, or fungal infection requiring systemic therapy or operative
             or radiological intervention.

         10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related
             illness.

         11. Liver transplant.

         12. Active malignancy other than HCC.

         13. Uncontrolled arterial hypertension or congestive heart failure (New York Heart
             Association Classification 3 or 4) (Appendix B).

         14. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery
             bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months
             prior to initiation of study drug.

         15. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of
             any grade, or persistent prolongation of the QTc (Fridericia) interval to &gt; 450 msec
             for males or &gt; 470 msec for females.

         16. Pregnant or lactating female.

         17. Any severe, acute, or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with trial participation or study
             drug administration; may interfere with the informed consent process and/or with
             compliance with the requirements of the trial; or may interfere with the
             interpretation of trial results and, in the Investigator's opinion, would make the
             subject inappropriate for entry into this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman</last_name>
    <role>Study Director</role>
    <affiliation>Can-Fite BioPharma Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael H Silverman, MD</last_name>
    <phone>972-3-9241114</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Purcell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Beg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petar Petrov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Central Onco Hospita</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Velko Minchev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Tokuda Hospital Sofia&quot; AD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krasimir Oreshkov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment for women's health - Nadezhda</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Taushanova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Serdica</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krassimir Koynov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Sveta Marina&quot; EAD</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitar Kalev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solomon Shtemer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Pelican Impex SRL- Sectia Oncologie Medicala</name>
      <address>
        <city>Bihor</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aniela PLATONA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni - Sectia Oncologie Medicala</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adina CROITORU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Bendis - Oncologie Medicala</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Calin CAINAP, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie ONCOLAB</name>
      <address>
        <city>Dolj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly CHERCIU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi - Sectia Oncologie Medicala</name>
      <address>
        <city>Iaşi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihai MARINCA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SC DACMED SRL - Oncologie</name>
      <address>
        <city>Prahova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amedeia NITA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalului Clinic Judetean de Urgenta - Sectia Oncologie Medicala</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica PATRAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta &quot;Sf. Ioan Cel Nou&quot; - sectia Oncologie Medicala</name>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doina Elena GANEA MOTAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vojnomedicinska Akademija Beograd</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nenad Manojlović, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zdravstveni Centar Kladovo Služba Onkologije</name>
      <address>
        <city>Kladovo</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sladjana Natošević, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinički Centar Niš Klinika za Onkologiju</name>
      <address>
        <city>Niš</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetislav Vrbić, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut za Onkologiju Vojvodine</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dušan Jovanović, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Child-Pugh Class B Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

